Dec 26 (Reuters) - FDA:
FDA: RECOMMENDS CHANGES TO LABELING FOR TRANSMUCOSAL BUPRENORPHINE PRODUCTS INDICATED TO TREAT OPIOID USE DISORDER - WEBSITE
FDA: RECOMMENDED CHANGES INTEND TO CLARIFY THAT NEITHER 16 MG/DAY NOR 24 MG/DAY SHOULD BE INTERPRETED AS MAXIMUM DOSAGES FOR BTODS
((Reuters.Briefs@thomsonreuters.com;))